Share Price and Basic Stock Data
Last Updated: October 10, 2025, 9:37 pm
| PEG Ratio | -1.11 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Hemant Surgical Industries Ltd, based in Mumbai, operates in the medical equipment industry. The company has a market capitalization of ₹300 Cr and a price-to-earnings ratio of 37.5. Looking at the sales trends, the quarterly and annual revenue figures indicate a stable growth pattern. Operating profit margins stand at 10%, reflecting a consistent performance in managing expenses and generating revenue.
Profitability and Efficiency Metrics
The company’s net profit stands at ₹8 Cr, with a return on equity (ROE) of 13.6% and return on capital employed (ROCE) of 16.4%. The interest coverage ratio of 15.21x indicates a comfortable position in meeting interest obligations. However, the cash conversion cycle data is not available, which could provide insights into the efficiency of the company’s working capital management. Overall, Hemant Surgical Industries demonstrates decent profitability and efficiency metrics compared to sector benchmarks.
Balance Sheet Strength and Financial Ratios
With reserves of ₹53 Cr and borrowings of ₹31 Cr, the company maintains a healthy balance sheet. The price-to-book value (P/BV) ratio of 2.53x suggests that the stock is trading at a reasonable valuation. The absence of the current ratio and quick ratio data limits a comprehensive assessment of liquidity. Hemant Surgical Industries appears to have a moderate level of leverage, as indicated by the debt-equity ratio, which could be an area for further scrutiny.
Shareholding Pattern and Investor Confidence
Promoters hold a significant stake of 73.56%, indicating a strong belief in the company’s growth prospects. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold minor stakes of 0.39% and 1.11%, respectively, while the public holds 24.93%. Changes in shareholding patterns can influence market perception and valuation. Analyzing these trends over time can provide valuable insights into investor sentiment and confidence in the company.
Outlook, Risks, and Final Insight
Looking ahead, Hemant Surgical Industries could capitalize on the growing demand for medical equipment and technology advancements in the healthcare sector. However, risks such as regulatory changes, intense competition, and economic uncertainties could impact the company’s performance. Strengthening operational efficiency, diversifying product offerings, and enhancing investor communication could bolster future prospects. In conclusion, Hemant Surgical Industries presents a mixed outlook with growth opportunities tempered by inherent industry risks.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Hemant Surgical Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Hemant Surgical Industries Ltd | 322 Cr. | 309 | 367/88.2 | 40.3 | 60.3 | 0.00 % | 16.4 % | 13.6 % | 10.0 |
| Industry Average | 322.00 Cr | 309.00 | 40.30 | 60.30 | 0.00% | 16.40% | 13.60% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 8 | 4 | 6 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 |
Last Updated: May 31, 2025, 8:57 am
Below is a detailed analysis of the quarterly data for Hemant Surgical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 58.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Sep 2024) to 58.00 Cr., marking an increase of 9.00 Cr..
- For Expenses, as of Mar 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 45.00 Cr. (Sep 2024) to 52.00 Cr., marking an increase of 7.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Mar 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 7.00% (Sep 2024) to 10.00%, marking an increase of 3.00%.
- For Other Income, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
- For Tax %, as of Mar 2025, the value is 18.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Sep 2024) to 18.00%, marking a decrease of 11.00%.
- For Net Profit, as of Mar 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Sep 2024) to 5.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 4.74. The value appears strong and on an upward trend. It has increased from 3.05 (Sep 2024) to 4.74, marking an increase of 1.69.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 5:17 pm
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 |
| OPM % | 5% | 5% | 5% | 5% | 6% | 10% | 10% | 9% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -100.00% | 400.00% | 60.00% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -100.00% | 500.00% | -340.00% | -35.00% | -45.00% |
Hemant Surgical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 2% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | 20% |
| TTM: | -18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 80% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 22% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 6:30 am
Balance Sheet
Last Updated: October 10, 2025, 2:12 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 |
Below is a detailed analysis of the balance sheet data for Hemant Surgical Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2024) to 53.00 Cr., marking an increase of 9.00 Cr..
- For Borrowings, as of Mar 2025, the value is 31.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7.00 Cr. (Mar 2024) to 31.00 Cr., marking an increase of 24.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 54.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 148.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2024) to 40.00 Cr., marking an increase of 22.00 Cr..
- For CWIP, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 12.00 Cr., marking an increase of 12.00 Cr..
- For Investments, as of Mar 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 94.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2024) to 94.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Mar 2025, the value is 148.00 Cr.. The value appears strong and on an upward trend. It has increased from 100.00 Cr. (Mar 2024) to 148.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (53.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.00 | -8.00 | -11.00 | -11.00 | -4.00 | 4.00 | 3.00 | -22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 100.00 |
| Basic EPS (Rs.) | 9.85 | 10.28 | 8.96 | 2.22 | 32.90 |
| Diluted EPS (Rs.) | 9.85 | 10.28 | 8.96 | 2.22 | 32.90 |
| Cash EPS (Rs.) | 10.37 | 11.07 | 26.81 | 8.90 | 73.82 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 52.55 | 30.73 | 65.74 | 42.67 | 400.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 52.55 | 30.73 | 65.74 | 42.67 | 400.80 |
| Revenue From Operations / Share (Rs.) | 101.16 | 142.12 | 517.85 | 298.82 | 2805.11 |
| PBDIT / Share (Rs.) | 14.16 | 16.69 | 42.50 | 19.81 | 150.54 |
| PBIT / Share (Rs.) | 13.17 | 15.59 | 38.76 | 16.64 | 119.62 |
| PBT / Share (Rs.) | 12.24 | 13.10 | 30.56 | 7.60 | 47.90 |
| Net Profit / Share (Rs.) | 9.39 | 9.96 | 23.07 | 5.73 | 42.90 |
| PBDIT Margin (%) | 13.99 | 11.74 | 8.20 | 6.62 | 5.36 |
| PBIT Margin (%) | 13.02 | 10.96 | 7.48 | 5.56 | 4.26 |
| PBT Margin (%) | 12.10 | 9.21 | 5.90 | 2.54 | 1.70 |
| Net Profit Margin (%) | 9.27 | 7.00 | 4.45 | 1.91 | 1.52 |
| Return on Networth / Equity (%) | 17.86 | 32.42 | 35.09 | 13.42 | 10.70 |
| Return on Capital Employeed (%) | 23.37 | 44.37 | 44.51 | 16.47 | 14.29 |
| Return On Assets (%) | 10.14 | 11.78 | 8.48 | 2.66 | 2.07 |
| Long Term Debt / Equity (X) | 0.06 | 0.12 | 0.31 | 1.21 | 1.09 |
| Total Debt / Equity (X) | 0.12 | 0.30 | 0.74 | 1.69 | 1.76 |
| Asset Turnover Ratio (%) | 1.31 | 1.83 | 2.13 | 1.42 | 1.50 |
| Current Ratio (X) | 1.83 | 1.23 | 1.02 | 1.13 | 1.05 |
| Quick Ratio (X) | 1.28 | 0.84 | 0.67 | 0.47 | 0.45 |
| Inventory Turnover Ratio (X) | 4.47 | 5.93 | 5.89 | 3.32 | 3.88 |
| Interest Coverage Ratio (X) | 15.21 | 6.70 | 5.19 | 2.19 | 2.10 |
| Interest Coverage Ratio (Post Tax) (X) | 11.09 | 5.00 | 3.81 | 1.63 | 1.60 |
| Enterprise Value (Cr.) | 132.59 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 1.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 8.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 1.32 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 1.32 | 0.00 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Hemant Surgical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 9.85. This value is within the healthy range. It has decreased from 10.28 (Mar 23) to 9.85, marking a decrease of 0.43.
- For Diluted EPS (Rs.), as of Mar 24, the value is 9.85. This value is within the healthy range. It has decreased from 10.28 (Mar 23) to 9.85, marking a decrease of 0.43.
- For Cash EPS (Rs.), as of Mar 24, the value is 10.37. This value is within the healthy range. It has decreased from 11.07 (Mar 23) to 10.37, marking a decrease of 0.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.55. It has increased from 30.73 (Mar 23) to 52.55, marking an increase of 21.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.55. It has increased from 30.73 (Mar 23) to 52.55, marking an increase of 21.82.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 101.16. It has decreased from 142.12 (Mar 23) to 101.16, marking a decrease of 40.96.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 14.16. This value is within the healthy range. It has decreased from 16.69 (Mar 23) to 14.16, marking a decrease of 2.53.
- For PBIT / Share (Rs.), as of Mar 24, the value is 13.17. This value is within the healthy range. It has decreased from 15.59 (Mar 23) to 13.17, marking a decrease of 2.42.
- For PBT / Share (Rs.), as of Mar 24, the value is 12.24. This value is within the healthy range. It has decreased from 13.10 (Mar 23) to 12.24, marking a decrease of 0.86.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 9.39. This value is within the healthy range. It has decreased from 9.96 (Mar 23) to 9.39, marking a decrease of 0.57.
- For PBDIT Margin (%), as of Mar 24, the value is 13.99. This value is within the healthy range. It has increased from 11.74 (Mar 23) to 13.99, marking an increase of 2.25.
- For PBIT Margin (%), as of Mar 24, the value is 13.02. This value is within the healthy range. It has increased from 10.96 (Mar 23) to 13.02, marking an increase of 2.06.
- For PBT Margin (%), as of Mar 24, the value is 12.10. This value is within the healthy range. It has increased from 9.21 (Mar 23) to 12.10, marking an increase of 2.89.
- For Net Profit Margin (%), as of Mar 24, the value is 9.27. This value is within the healthy range. It has increased from 7.00 (Mar 23) to 9.27, marking an increase of 2.27.
- For Return on Networth / Equity (%), as of Mar 24, the value is 17.86. This value is within the healthy range. It has decreased from 32.42 (Mar 23) to 17.86, marking a decrease of 14.56.
- For Return on Capital Employeed (%), as of Mar 24, the value is 23.37. This value is within the healthy range. It has decreased from 44.37 (Mar 23) to 23.37, marking a decrease of 21.00.
- For Return On Assets (%), as of Mar 24, the value is 10.14. This value is within the healthy range. It has decreased from 11.78 (Mar 23) to 10.14, marking a decrease of 1.64.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.12 (Mar 23) to 0.06, marking a decrease of 0.06.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.30 (Mar 23) to 0.12, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 1.31. It has decreased from 1.83 (Mar 23) to 1.31, marking a decrease of 0.52.
- For Current Ratio (X), as of Mar 24, the value is 1.83. This value is within the healthy range. It has increased from 1.23 (Mar 23) to 1.83, marking an increase of 0.60.
- For Quick Ratio (X), as of Mar 24, the value is 1.28. This value is within the healthy range. It has increased from 0.84 (Mar 23) to 1.28, marking an increase of 0.44.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.47. This value is within the healthy range. It has decreased from 5.93 (Mar 23) to 4.47, marking a decrease of 1.46.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 15.21. This value is within the healthy range. It has increased from 6.70 (Mar 23) to 15.21, marking an increase of 8.51.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 11.09. This value is within the healthy range. It has increased from 5.00 (Mar 23) to 11.09, marking an increase of 6.09.
- For Enterprise Value (Cr.), as of Mar 24, the value is 132.59. It has increased from 0.00 (Mar 23) to 132.59, marking an increase of 132.59.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 1.26, marking an increase of 1.26.
- For EV / EBITDA (X), as of Mar 24, the value is 8.97. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 8.97, marking an increase of 8.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.32. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 1.32, marking an increase of 1.32.
- For Price / BV (X), as of Mar 24, the value is 2.53. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 2.53, marking an increase of 2.53.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.32. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 1.32, marking an increase of 1.32.
- For EarningsYield, as of Mar 24, the value is 0.07. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 23) to 0.07, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hemant Surgical Industries Ltd:
- Net Profit Margin: 9.27%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.37% (Industry Average ROCE: 16.4%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.86% (Industry Average ROE: 13.6%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.09
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40.3 (Industry average Stock P/E: 40.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.27%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | 502, 5th Floor, Ecstasy Business Park Co-Op Socteiy Limited, Mumbai Maharashtra 400080 | info@hemantsurgical.com http://www.hemantsurgical.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hanskumar Shah | Chairman & Managing Director |
| Mr. Kaushik Hanskumar Shah | WholeTime Director & CFO |
| Mr. Hemant Praful Shah | Whole Time Director |
| Mrs. Nehal Babu Karelia | Non Executive Director |
| Mr. Ketan Chandrakat Dave | Independent Director |
| Mrs. Kshama Dharnidharka | Independent Director |
FAQ
What is the intrinsic value of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd's intrinsic value (as of 10 October 2025) is 269.68 which is 12.72% lower the current market price of 309.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹322 Cr. market cap, FY2025-2026 high/low of 367/88.2, reserves of ₹53 Cr, and liabilities of 148 Cr.
What is the Market Cap of Hemant Surgical Industries Ltd?
The Market Cap of Hemant Surgical Industries Ltd is 322 Cr..
What is the current Stock Price of Hemant Surgical Industries Ltd as on 10 October 2025?
The current stock price of Hemant Surgical Industries Ltd as on 10 October 2025 is 309.
What is the High / Low of Hemant Surgical Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hemant Surgical Industries Ltd stocks is 367/88.2.
What is the Stock P/E of Hemant Surgical Industries Ltd?
The Stock P/E of Hemant Surgical Industries Ltd is 40.3.
What is the Book Value of Hemant Surgical Industries Ltd?
The Book Value of Hemant Surgical Industries Ltd is 60.3.
What is the Dividend Yield of Hemant Surgical Industries Ltd?
The Dividend Yield of Hemant Surgical Industries Ltd is 0.00 %.
What is the ROCE of Hemant Surgical Industries Ltd?
The ROCE of Hemant Surgical Industries Ltd is 16.4 %.
What is the ROE of Hemant Surgical Industries Ltd?
The ROE of Hemant Surgical Industries Ltd is 13.6 %.
What is the Face Value of Hemant Surgical Industries Ltd?
The Face Value of Hemant Surgical Industries Ltd is 10.0.